PharmaShots | Incisive News in 3 Shots

Subscribe Now

chronic inflammatory diseases

Boehringer Ingelheim's Cyltezo (biosimilar- adalimumab) Receives the US FDA's sBLA Approval as the 1st Interchangeable Biosimilar for Multiple Chronic Inflammatory Diseases

Boehringer Ingelheim's Cyltezo (biosimilar- adalimumab) Receives the US FDA's sBLA Approval as the 1st Interchangeable Biosimilar...

October 18, 2021

Amgen Collaborates with Orion for Commercialization of Amgevita (adalimumab- biosimilar) in Finland

Amgen Collaborates with Orion for Commercialization of Amgevita (adalimumab- biosimilar) in Finland

October 25, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us